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Objectives The aim of this study was to evaluate the risks and benefits of short-term anticoagulation in patients receiving
aortic valve bioprostheses.
Background Patients receiving aortic valve bioprostheses have an elevated early risk of thromboembolic events; however, the
risks and benefits of short-term anticoagulation have been debated with limited evidence.
Methods Our cohort consisted of 25,656 patients 65 years of age receiving aortic valve bioprostheses at 797 hospitals
within the Society of Thoracic Surgeons Adult Cardiac Surgery Database (2004 to 2006). The associated
3-month incidences of death or readmission for embolic (cerebrovascular accident, transient ischemic attack,
and noncerebral arterial thromboembolism) or bleeding events were compared across discharge anticoagulation
strategies with propensity methods.
Results In this cohort (median age, 77 years), the 3 most common discharge anticoagulation strategies included:
aspirin-only (49%), warfarin-only (12%), and warfarin plus aspirin (23%). Among those receiving aspirin-only,
3-month adverse events were low (death, 3.0%; embolic events, 1.0%; bleeding events, 1.0%). Relative to
aspirin-only, those treated with warfarin plus aspirin had a lower adjusted risk of death (relative risk [RR]: 0.80,
95% confidence interval [CI]: 0.66 to 0.96) and embolic event (RR: 0.52, 95% CI: 0.35 to 0.76) but a higher risk
of bleeding (RR: 2.80, 95% CI: 2.18 to 3.60). Relative to aspirin-only, warfarin-only patients had a similar risk of
death (RR: 1.01, 95% CI: 0.80 to 1.27), embolic events (RR: 0.95, 95% CI: 0.61 to 1.47), and bleeding
(RR: 1.23, 95% CI: 0.85 to 1.79). These results were generally consistent across patient subgroups.
Conclusions Death and embolic events were relatively rare in the first 3 months after bioprosthetic aortic valve replacement.
Compared with aspirin-only, aspirin plus warfarin was associated with a reduced risk of death and embolic
events, but at the cost of an increased bleeding risk. (J Am Coll Cardiol 2012;60:971–7) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.029Despite having a low long-term risk of thromboembolism,
patients treated with aortic valve bioprostheses carry a modest
early (90 days) risk of embolic events (1). The extent to
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theless, the use of antithrombotic
agents early after bioprosthetic
valve implantation remains com-
mon (2,3,7,8).
In this analysis, we used a
contemporary cohort of patients
from the Society of Thoracic
Surgeons Adult Cardiac Surgery
Database (STS ACSD) to evaluate:
See page 978
1) contemporary patterns of post-
discharge anticoagulation after bio-
prosthetic aortic valve replacement (AVR); 2) the absolute risk of
early (90 days) thromboembolic and bleeding events in this
etting; and 3) the relative safety and effectiveness of both warfarin
lus aspirin and warfarin-only versus aspirin-only in the early
ost-operative interval.
ethods
ata source and study population. The STS ACSD
collects detailed in-hospital data on adult patients undergoing
cardiac surgery at more than 1,000 participating institutions
throughout the United States. Patient follow-up is accom-
plished for older individuals (65 years of age) through a
deterministic linkage process with Medicare inpatient insur-
ance claims files (9). For purposes of this analysis, STS ACSD
records were linked to Part A Medicare Provider and Analysis
Review (MedPAR) files with indirect patient identifiers (i.e.,
age and sex, as well as dates of birth, admission, and discharge;
linkage rate, 75.5%). Compared with patients in the linked
population, eligible patients who were not linked to Medicare
records were (on average) slightly younger, less often female,
less often Caucasian, and more often from the Mid-Atlantic
and Pacific Northwest regions. Otherwise, linked and unlinked
patients were similar across demographic data and comorbidi-
ties of interest.
From the Medicare-linked ACSD cohort, we identified a
group of 29,395 fee-for-service patients without a history of
prior valve surgery, undergoing elective or urgent isolated
AVR with a stented bioprosthesis (with or without con-
comitant coronary artery bypass grafting) at 800 centers
from January 1, 2004, to December 28, 2006. We excluded
patients in whom clinical equipoise was unlikely, including
those with a pre-operative indication for warfarin, an
indwelling mechanical heart valve, a pre-discharge contra-
indication to warfarin therapy, a complication related to
anticoagulation, or an adverse post-operative gastrointesti-
nal event. Additionally, we excluded patients who died
before hospital discharge and those missing data on sex, age,
or discharge medications. The Duke University School of
Medicine Institutional Review Board granted a waiver of
Abbreviations
and Acronyms
CI  confidence interval
MedPAR  Medicare
Provider and Analysis
Review
NNH  number-needed-
to-harm
NNT  number-needed-
to-treat
RR  risk ratio
STS ACSD  Society of
Thoracic Surgeons Adult
Cardiac Surgery Databaseinformed consent and authorization for this study. iPatient subgroups. Analyses were stratified by age (65 to 74
years of age, 75 years of age), sex, and thromboembolic risk
tatus. Consistent with American College of Cardiology/
merican Heart Association guidelines for the treatment of
atients with valvular heart disease (10), patients were consid-
red to be at an increased risk for early thromboembolic events
f they had a pre-discharge history of atrial fibrillation,
hromboembolism, or depressed ejection fraction (ejec-
ion fraction 30%).
tudy endpoints. Because this analysis was designed to
nvestigate the safety and effectiveness of discharge antico-
gulation strategies, all endpoints were evaluated from the
ime of hospital discharge. Primary endpoints included
eath or repeat hospital stay for embolic (including cere-
rovascular accident, transient ischemic attack, and nonce-
ebral arterial thromboembolism) or bleeding events (in-
luding hemorrhagic stroke, gastrointestinal bleeding, other
leeding). Secondary endpoints included repeat hospital
tay for individual embolic and bleeding events. Death after
ospital discharge was identified with the Medicare De-
ominator File, whereas nonfatal endpoints were identified
ith primary hospital diagnosis International Classification
f Diseases-Ninth Revision-Clinical Modification codes
Online Appendix). Repeat hospital stay for hemopericar-
ium was identified with STS records.
tatistical analysis. Baseline patient characteristics were
tratified by treatment strategy and summarized as percent-
ges for categorical variables and means with SD for
ontinuous variables. The Mantel-Haenszel test was used to
ompare the distribution of categorical variables between
roups, whereas the Wilcoxon rank sum test was used to
ompare continuous variable distributions. The SAS statis-
ical software (version 9.1, SAS Institute, Cary, North
arolina) was used for all calculations.
Propensity scores estimated the probability of patients re-
eiving either warfarin-only (vs. aspirin-only) or warfarin plus
spirin (vs. aspirin-only) at discharge as a function of 73
bserved covariates (Online Appendix) (11,12). Overlap of the
ropensity scores for each comparison validated the statistical
ppropriateness of this method, and comparability of baseline
haracteristics after propensity score weighting (Online Ap-
endix) suggested that the approach was successful.
Adjusted risk ratios (RRs) were estimated with general-
zed linear models (for binomial distribution) with a log link
unction, including a single covariate for treatment strategy
nd weighting each observation by the inverse of the
stimated propensity score (12,13). Robust sandwich vari-
nce estimates were used to obtain 95% confidence intervals
CIs) (14) to account for statistical dependence of patients
ithin sites. Adjusted risk differences were obtained by the
ame method, with an identity link function. Probabilities
re interpreted as risks in this closed cohort with complete
ollow-up and a low occurrence of death as a competing risk.
he adjusted numbers-needed-to-treat (NNT) or -harm
NNH) were calculated as the inverse of the risk difference
n the inverse probability weighted populations with similar
973JACC Vol. 60, No. 11, 2012 Brennan et al.
September 11, 2012:971–7 Anticoagulation Strategies for Bioprosthetic Valvesdistributions of measured patient characteristics and are
interpreted as an estimated average number of patients
needed to treat with either warfarin-only (vs. aspirin-only)
or warfarin plus aspirin (vs. aspirin-only) to result in 1 fewer
(NNT) or 1 more (NNH) associated event.
Sensitivity analysis. Due to a clinical concern that patient
frailty might have biased our treatment comparisons, we
analyzed the treatment effect for each of the 2 comparisons
within a “discharge-to-home” cohort that was expected to
have a low proportion of frail patients. Although the
incidence of adverse events was low in this cohort, the
treatment effects were similar to that observed in the overall
study cohort (Online Appendix).
Results
Population characteristics. The study cohort included
25,656 patients who survived to hospital discharge after
isolated AVR ( coronary artery bypass grafting) with a
stented bioprosthesis at 1 of 797 centers between 2004 and
2006 (Fig. 1). Within this patient cohort, the median age
was 77 years (interquartile range: 72 to 81 years), and 39.4%
were women. A prior history of at least 1 of the following
risk factors for early thromboembolism was present at
hospital discharge in 13,458 patients (risk factor positive:
52.5%): atrial fibrillation (41.1%), thromboembolism
(13.6%), or ejection fraction 30% (4.8%).
At hospital discharge, the 3 most prevalent anticoagula-
tion strategies included aspirin-only (n  12,457, 48.6%),
aspirin plus warfarin (n  5,972, 23.3%), and warfarin-only
Figure 1 Population Flow Diagram
Population flow diagram displays which patients were included and excluded from
BVR  bioprosthetic valve replacement; CABG  coronary artery bypass grafting; G(n  2,999, 11.7%). No anticoagulant was recommended in6.5% (Fig. 2). Institutional variation was high in both:
1) the proportion of patients treated with warfarin at
hospital discharge; and 2) the proportion of warfarin-treated
patients receiving aspirin plus warfarin (Online Appendix).
udy.
astrointestinal; STS  Society of Thoracic Surgeons.
Figure 2 Prevalence of Anticoagulation Strategies
Prevalence of anticoagulation strategies at hospital discharge after biopros-
thetic valve replacement (BVR). ADP  adenosine diphosphate; DAP  dual
antiplatelet therapy.the st
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d
3
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prevalent anticoagulation strategies are presented in Table 1.
Effectiveness of discharge anticoagulant strategies:
mortality. The 3-month incidence of death after hospital
ischarge was low (aspirin-only, 3.0%; aspirin plus warfarin,
.1%; warfarin-only, 4.0%). After risk adjustment, the
ddition of warfarin to aspirin was associated with a 0.6%
bsolute and 20% relative risk reduction for mortality at 3
onths (adjusted RR: 0.80, 95% CI: 0.66 to 0.96; NNT
Population Characteristics Stratified byDisch rge Anticoagula ion Tre m nt StrategyTable 1 Population Characteristics StratifieDischarge Anticoagulation Treatme
Aspirin-Only
(n  12,457)
Patient characteristics
Age, yrs 76.4 6.2
Women 40.5
Race
White 91.9
Black 3.1
Hispanic 1.7
Other 3.3
Smoking, current 8.2
BSA, m2 1.90 0.23
EF, % 54 13
CHF 34.1
Diabetes
Noninsulin 22.1
Insulin 7.0
Dialysis 1.5
PVD 13.9
Prior valve surgery 1.9
Mitral stenosis 2.5
Operative characteristics
Procedural status
Elective 72.9
Urgent 26.6
Other 0.6
AVR  CABG 55.2
Pre-discharge complications
Thromboembolism 1.3
Stroke 1.4
Bleeding 13.6
Renal failure 3.7
Prolonged ventilation or coma 8.9
Thromboembolic risk factors
Atrial fibrillation 32.9
EF 30% 4.5
Prior CVA 10.7
Any thromboembolism 12.9
Discharge location
Home 69.0
Nursing home 6.0
Extended care/TCU 22.0
Other hospital 1.2
Other 1.9
Values are mean  SD or %.
AVR  aortic valve replacement; BSA  body surface area; CABG  coro
cerebrovascular accident; EF  ejection fraction; PVD  peripheral vascular153) (Table 2)—this trend was consistent across strata of
age, sex, and thromboembolic risk (Fig. 3A). Warfarin-only
was not associated with a reduction in the risk of mortality
(vs. aspirin-only) (Table 2).
Effectiveness of discharge anticoagulant strategies: embolic
events. The 3-month incidence of embolic events after
hospital discharge was low (0.9%); however, the majority of
events (71.5%) were neurologic, and repeat hospital stay for
stroke was associated with a 3.9% unadjusted risk of
rategy
arfarin-Only
(n  2,999)
Aspirin  Warfarin
(n  5,972) p Value
77.0 6.0 76.6 5.8 0.0001
41.4 37.1 0.0001
0.0001
92.2 94.4
2.0 2.0
2.4 1.3
3.4 2.3
6.6 7.9 0.02
1.91 0.23 1.93 0.22 0.0001
55.0 13 53 13 0.0003
38.5 34.9 0.0001
0.03
20.7 23.6
6.8 7.1
0.9 1.1 0.02
13.5 13.8 0.9
2.8 2.2 0.01
1.9 2.5 0.1
0.002
73.8 70.5
25.4 28.9
0.8 0.7
44.6 60.9 0.0001
2.0 1.8 0.003
2.4 1.9 0.001
17.0 16.4 0.0001
4.5 3.9 0.2
10.2 9.3 0.09
58.2 58.0 0.0001
4.3 5.4 0.01
11.8 11.9 0.03
15.2 15.0 0.0001
0.001
65.9 67.2
7.5 7.3
23.2 22.3
1.5 1.2
1.6 2.0d by
nt St
Wnary artery bypass grafting; CHF  congestive heart failure; CVA 
disease; TCU  transitional care unit.
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incidence of embolic events was higher among patients with
(vs. without) characteristics thought to be associated with an
early risk of thromboembolism (1.30% vs. 0.81%). The
addition of warfarin to aspirin was associated with a 0.4%
absolute reduction (48% relative reduction) in the 3-month
risk of embolic events (p  0.006) in the overall cohort, an
association that was preserved after risk adjustment (ad-
justed RR: 0.51, 95% CI: 0.50 to 0.97; NNT 212) (Table 2).
This effect was most prominent among the oldest (75
years of age) patients (adjusted RR: 0.44, 95% CI: 0.27 to
0.72; NNT 143) (Fig. 3B). In the overall cohort, warfarin-
only was not associated with a reduction in the risk of
embolic events at 3 months (vs. aspirin-only) (Table 2), a
result that was consistent across most subgroups.
Effectiveness of discharge anticoagulant strategies:
bleeding events. The incidence of bleeding requiring re-
peat hospital stay by 3 months after hospital discharge was
low (1.6%), and the majority of bleeding events (77.5%)
involved the gastrointestinal tract. Hemopericardium was
rare among patients treated with aspirin-only (0.36%) but
was more common among those treated with warfarin plus
aspirin (0.77%) or warfarin-only (1.0%). Likewise, hemor-
rhagic stroke was extremely rare in the aspirin-only cohort
(0.11%) but was slightly more common among patients
treated with warfarin plus aspirin (0.16%) or warfarin-only
(0.21%). Overall, repeat hospital stay for bleeding was
associated with a 3.5% unadjusted risk of mortality within
the subsequent 2 weeks. The unadjusted 3-month incidence of
repeat hospital stay for a bleeding event was higher among
those in whom warfarin was added to aspirin at hospital
discharge (2.8% vs. 1.0%, p  0.0001). This effect persisted
fter risk adjustment (RR: 2.80, 95% CI: 2.18 to 3.60, NNH
5) (Fig. 3C, Table 2). Warfarin-only was not associated with
higher risk-adjusted incidence of repeat hospital stay for
leeding compared with aspirin-only (Table 2).
iscussion
his analysis is the first large-scale evaluation of anticoag-
lation strategies at hospital discharge after bioprosthetic
VR in the United States. In contemporary practice, there
xists considerable variation in anticoagulation strategies,
nd aspirin alone remains a common regimen. Although the
isk of early embolic events is relatively low in patients
Outcomes at 3 Months With Anticoagulant Strategies in the OveraReceiving Aortic Valve BioprosthesesTable 2 Outcomes at 3 Months With Anticoagulant S rategi sReceiving Aortic Valve Bioprostheses
Unadjusted 3-Month Incidence (%)
Aspirin-Only
(n  12,457)
Warfarin-Only
(n  2,999)
Death 3.0 4.0
Embolism 1.0 1.0
Bleeding 1.0 1.4
CI  confidence interval; RR  risk ratio.reated with aspirin-only, those treated with warfarin plusaspirin at hospital discharge experience a lower adjusted
incidence of early embolic events—a benefit that is balanced
by an increased risk of repeat hospital stay for bleeding.
Considerable disagreement persists with regard to the
appropriate anticoagulant strategy in the first 3 months after
bioprosthetic AVR. Based primarily on expert consensus
(Class IIa, Level of Evidence: C), the American College of
Cardiology/American Heart Association guidelines have
recommended the addition of warfarin to aspirin at hospital
discharge for all patients receiving a bioprosthetic AVR
(10); however, 2 major international surveys have demon-
strated that many practicing cardiac surgeons do not en-
dorse this recommendation (2,3). Our data demonstrate
diverse practice patterns within the United States, with
warfarin use observed in a minority of these patients (35%).
The diversity of discharge strategies is a testament to the
limitations of available evidence.
To date, evidence guiding the selection of anticoagulants
has been limited (15). Single-center observational studies
evaluating the addition of warfarin to aspirin at hospital
discharge have failed to detect a difference in either bleeding
or embolic outcomes (16–20), and 2 small randomized pilot
studies evaluating the use of vitamin K antagonism in this
setting have also not detected a treatment difference (total
n  268) (5,6). Our analysis is the first to address this
question with a cohort that is adequately powered to detect
a difference in these serious but relatively rare outcomes.
Significantly, our analysis further evaluates the consistency
of these results in important patient subgroups. Although
observational in nature, this analysis suggests a beneficial
treatment effect of antithrombotic agents for the prevention
of early embolic events when added to antiplatelet agents at
hospital discharge in patients receiving bioprosthetic AVR.
The addition of warfarin to aspirin at hospital discharge
would be a reasonable treatment option, on the basis of
these results, with an expected number needed to avert 1
death of 153 patients and 1 embolic event of 212 patients.
The therapeutic benefit observed with the addition of
warfarin to aspirin was not without risk in this elderly
cohort, and 1 additional bleeding event was observed at 3
months for every 55 patients treated with warfarin. The
majority of these additional bleeding events involved read-
mission for gastrointestinal bleeding, and no difference in
the incidence of hemorrhagic stroke was observed across the
ulation of Patientse Overall Population of Patients
Adjusted RR (95% CI)
in  Warfarin
 5,972)
Warfarin-Only vs.
Aspirin-Only
Warfarin  Aspirin vs.
Aspirin-Only
3.1 1.01 (0.80–1.27) 0.80 (0.66–0.96)
0.6 0.95 (0.61–1.47) 0.52 (0.35–0.76)
2.8 1.23 (0.85–1.79) 2.80 (2.18–3.60)ll Popin th
Aspir
(n2 treatment strategies. Nevertheless, these events were not
976 Brennan et al. JACC Vol. 60, No. 11, 2012
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absolute 3.5% increase in the risk of mortality over the
subsequent 2 weeks. This finding highlights the complexity
associated with this therapeutic decision and the need for a
Figure 3 Adjusted RR at 3 Months
Adjusted relative risk (RR) of anticoagulation strategies at hospital discharge after
3 months; (B) embolism, 3 months; and (C) bleeding, 3 months. For each endpo
(b) warfarin plus aspirin versus aspirin-only. CI  confidence interval.balanced discussion of alternative treatment strategies.Study limitations. First, although our study is an exploration
of the relative safety and effectiveness of discharge anticoagu-
lant strategies in a real-world setting, and these data reflect
real-world practice, they are still observational in nature. As a
bioprosthetic valve replacement (BVR) in patient subgroups for: (A) death,
est plots compare patients treated with (a) warfarin-only versus aspirin-only; andaortic
int, Forresult, treatment comparisons might be subject to certain
y977JACC Vol. 60, No. 11, 2012 Brennan et al.
September 11, 2012:971–7 Anticoagulation Strategies for Bioprosthetic Valvesbiases, including treatment selection bias. Additionally, subtle
differences between the Medicare-linked and Medicare-
eligible STS ACSD cohorts might limit the generalizability of
these results. Second, this analysis was performed with inpa-
tient insurance claims for outcome ascertainment and might
underestimate the risk of both bleeding and embolic events in
this population, especially for minor “nuisance” events that are
less likely to provoke a hospital admission. Finally, although
most repeat hospital stay events of Medicare fee-for-service
patients are captured with MedPAR billing data, a small subset
might occur at hospitals that do not file Medicare claims. This
is not expected to have biased the observed treatment effect, but
it might have led to an underestimation of the incidence of
repeat hospital stay in this cohort.
Conclusions
The early risk of embolic events is low in patients receiving
bioprosthetic AVR, and considerable practice variation exists
in the selection of discharge anticoagulants in the United
States. Although a warfarin plus aspirin strategy was associated
with a higher risk of bleeding (vs. aspirin only), the early risk of
embolic events was lower among patients treated with this
strategy. Given the clear trade-off between thromboembolic
and bleeding events, we would recommend the use of warfarin
plus aspirin for bioprosthetic aortic valve patients thought to be
at low risk for bleeding complications, with an aspirin-only
strategy reserved for those thought to be at high risk for
bleeding.
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